Pharmafile Logo
Pharmafocus logo
Advanced Search

CNS

Showing 15 posts of 22 posts found.

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023
Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …

News

Perception and Otsuka enter collaboration and licensing deal for depression drug candidate

March 16, 2021
Manufacturing and Production CNS, Otsuka Pharmaceutical, Perception Neuroscience, depression

Perception Neuroscience and Otsuka Pharmaceutical have announced a collaboration and licensing agreement for the development and commercialisation of Perception’s lead …

News

Novartis’ Mayzent granted license by the European Medicines Agency

January 21, 2020
Manufacturing and Production CNS, European Medicines Agency, NHS, NICE, Novartis

The European Medicines Agency (EMA) has granted a licence for the use of Mayzent (siponimod) in the treatment of certain …

News

Takeda opens R&D facility in San Diego, California

May 2, 2019
Manufacturing and Production, Research and Development CNS, GI, Japan, Takeda, california, neuroscience, san diego

Japanese-firm Takeda pharmaceuticals has opened a new research facility in San Diego, California. The 165,000ft2 research centre will employ 250 …

News

CBD could be used to deliver drugs into the brain, research shows

April 18, 2019
Research and Development BBB, CBD, CNS, brain, drug delivery, neuroscience

Cannabidiol (CBD), one of 113 cannabinoids in cannabis plants, could be used to deliver medicines into the brain, according to …

News
eisa0008_web

Biogen and Eisai discontinue Phase 3 Alzheimer’s trial

March 21, 2019
Research and Development Alzheimer's, Biogen, CNS, Eisai, mental health

Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of …

News

Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect

February 15, 2019
Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …

News
pharmafile_srping_2018_cover

The new and improved Spring 2018 edition of Pharmafile is available to read online now!

May 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CNS, Cancer, Pharmafocus, cardiovascular, cvd, oncology, pharmafile

The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in …

News
biology-think-networking-physiology-brain-anatomy-2676370

Pfizer begins sell-off, shedding CNS drug to Biogen for $590m

March 13, 2018
Manufacturing and Production, Sales and Marketing Biogen, CNS, Pfizer, biotech, drugs, pharma, pharmaceutical

Pfizer’s decision to back out of the neuroscience space was a strategic move that send shudders through the entire industry, …

News
Teva image

Teva buys majority stake in genomic analysis firm

August 4, 2015
Manufacturing and Production, Research and Development, Sales and Marketing CNS, Immuneering, Teva, central nervous system, genetic analysis

Teva has agreed to by a 51% equity share of genomic-analysis company Immuneering to advance treatments for diseases of the …

News
Teva image

Teva bolsters neurology unit through Auspex deal

March 31, 2015
Sales and Marketing CNS, SD-809, Teva, Tourette syndrome, auspex, deutetrabenazine, neurology

Teva is significantly enhancing its neurology business by acquiring US biopharma firm Auspex in a deal worth $3.5 billion. Teva …

News
Forest image

Forest sold to Actavis for $25 billion

February 18, 2014
Sales and Marketing Actavis, CNS, Forest, acquisition, labs, merger, synergy

The rumours of a substantial deal for Forest have been proven true after Actavis announced this afternoon that it will …

News

Allergan in $958m neurology deal

January 25, 2013
Sales and Marketing Allergan, CNS, MAP Pharmaceuticals, migraine

Allergan is to pay $958m for MAP Pharmaceuticals in a deal which sees both companies hoping to reap the benefits …

News
Takeda HQ image

Takeda to buy Envoy Therapeutics

November 7, 2012
Research and Development, Sales and Marketing CNS, Envoy, Parkinson's, Parkinsons, Takeda

Takeda Pharmaceutical Company has bought another private US firm, its second in as many months. The Japanese group is paying …

News
Halaven image

UK at centre of Eisai plans

September 18, 2012
Research and Development, Sales and Marketing CNS, Cancer Drugs Fund, Eisai, Fycompa, Halaven

Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as …

News

Latest content

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023